Commerzbank Aktiengesellschaft FI Purchases Shares of 5,814 Moderna, Inc. $MRNA

Commerzbank Aktiengesellschaft FI purchased a new position in Moderna, Inc. (NASDAQ:MRNA) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 5,814 shares of the company’s stock, valued at approximately $407,000.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Moderna by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock worth $1,226,335,000 after buying an additional 399,487 shares in the last quarter. Capital World Investors bought a new position in Moderna during the fourth quarter valued at approximately $378,299,000. Invesco Ltd. grew its holdings in Moderna by 15.7% during the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after buying an additional 1,115,131 shares in the last quarter. Theleme Partners LLP grew its holdings in Moderna by 8.6% during the 2nd quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock valued at $217,100,000 after buying an additional 626,420 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Moderna by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock worth $136,290,000 after acquiring an additional 309,126 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of research reports. Royal Bank Of Canada reiterated a “sector perform” rating and set a $130.00 target price on shares of Moderna in a research report on Wednesday. Wolfe Research reiterated an “underperform” rating and set a $25.00 price objective on shares of Moderna in a research report on Monday, July 20th. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research note on Wednesday. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a research report on Wednesday. Finally, Citigroup lifted their price target on Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $56.56.

Moderna Trading Up 177.0%

MRNA opened at $174.38 on Thursday. The stock has a market cap of $69.62 billion, a price-to-earnings ratio of -21.82 and a beta of 0.91. The stock’s 50 day moving average price is $64.91 and its 200-day moving average price is $54.84. Moderna, Inc. has a one year low of $22.28 and a one year high of $176.66. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period in the prior year, the business posted ($2.13) earnings per share. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, equities analysts forecast that Moderna, Inc. will post -6.18 EPS for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the sale, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.80% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Phase 3 melanoma trial met both key endpoints. Intismeran, Moderna’s individualized mRNA neoantigen therapy, combined with Merck’s Keytruda, significantly improved recurrence-free survival and distant metastasis-free survival versus Keytruda alone in patients with resected, high-risk melanoma. The companies described the results as the first positive late-stage trial for a personalized mRNA cancer vaccine. Merck and Moderna Phase 3 trial announcement
• Positive Sentiment: The results support a broader cancer-treatment opportunity. Analysts and medical commentators said the outcome could validate Moderna’s mRNA platform for treating cancer and potentially open development opportunities across additional tumor types. The vaccine is tailored to mutations in an individual patient’s tumor, offering a potentially differentiated approach to personalized oncology. Moderna and Merck cancer vaccine breakthrough
• Positive Sentiment: Additional developments added to the bullish sentiment. The FDA approved Moderna’s first mRNA-based seasonal influenza vaccine, mFLUSIVA, while William Blair upgraded the stock to “outperform” and Bank of America moved its rating from “underperform” to “neutral.” FDA approval of Moderna mFLUSIVA
• Neutral Sentiment: Investors are awaiting detailed trial data. Moderna and Merck released topline results, but analysts said full efficacy, safety and durability data will be important for assessing regulatory timing and the vaccine’s commercial potential.
• Negative Sentiment: The sharp rally raises execution and valuation risks. The move triggered substantial losses for short sellers and increased options activity, while the stock now reflects much higher expectations for successful approval, manufacturing and adoption. Any disappointing detailed data or regulatory delays could lead to volatility.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.